Preclinical · IND-enabling · Phase 1Tx
Therapeutics
Tracking program spend across discovery, lead optimization, and IND-enabling studies. CRO accruals, milestone payments, and per-program R&D allocation that holds up under auditor scrutiny.
§ Sector Specialization
Where the practice runs deepest.
We don't claim to know every industry. We know this one. The CRO accrual quirks, the per-program cost allocation auditors want to see, and the way your investors think about runway versus catalyst.
Assay dev · Validation · Early commercialDx
Diagnostics
From wet-lab assay development through CLIA validation. We handle reagent costing, sample-throughput unit economics, and the COGS build investors will want to see at Series A.
Prototyping · 510(k) prep · Pilot manufacturingDv
Medical Devices
Capitalized engineering work, tooling and mold accounting, regulatory consulting spend, and clinical-trial budgeting. We've seen the surprises that hit at first audit and we route around them.
Service revenue · Multi-client billingLs
Lab Services & CROs
Project-level revenue recognition, milestone billing, and gross-margin reporting per service line. Built for shops moving from founder-led project management to a real ops finance function.
Software-meets-scienceDh
Digital Health & Bioinformatics
Hybrid SaaS + wet-lab P&Ls, cloud compute as COGS vs R&D treatment, and the deferred revenue mechanics your software-savvy investors will probe.
Hardware · Reagents · ConsumablesRt
Research Tools
Inventory accounting, distributor channel reconciliation, international sales tax, and the hardware-software split that tools companies routinely miscategorize.
§ Stages we serve
Pre-seed through Series B.
Pre-seed / Seed
Get the books right from the start. Don't pay later to fix what's broken now.
Series A
Audit-ready statements, clean monthly close, board-pack rhythm.
Series B
Fractional controllership, ASC 842 lease accounting, multi-program reporting.